Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Treatment guidelines suggest distinctive medication strategies for first-episode and multiepisode patients with schizophrenia. To assess the extent to which community clinicians adjust their usual treatment regimens for first-episode patients, the authors examined prescription patterns and factors associated with prescription choice in a national cohort of early-phase patients. METHOD: Prescription data at study entry were obtained from 404 participants in the Recovery After an Initial Schizophrenia Episode Project's Early Treatment Program (RAISE-ETP), a nationwide multisite effectiveness study for patients with first-episode schizophrenia spectrum disorders. Treatment with antipsychotics did not exceed 6 months at study entry. RESULTS: The authors identified 159 patients (39.4% of the sample) who might benefit from changes in their psychotropic prescriptions. Of these, 8.8% received prescriptions for recommended antipsychotics at higher than recommended dosages; 32.1% received prescriptions for olanzapine (often at high dosages), 23.3% for more than one antipsychotic, 36.5% for an antipsychotic and also an antidepressant without a clear indication, 10.1% for psychotropic medications without an antipsychotic, and 1.2% for stimulants. Multivariate analysis showed evidence for sex, age, and insurance status effects on prescription practices. Racial and ethnic effects consistent with effects reported in previous studies of multiepisode patients were found in univariate analyses. Despite some regional variations in prescription practices, no region consistently had different practices from the others. Diagnosis had limited and inconsistent effects. CONCLUSIONS: Besides prescriber education, policy makers may need to consider not only patient factors but also service delivery factors in efforts to improve prescription practices for first-episode schizophrenia patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Why We (Usually) Don't Have to Worry About Multiple Comparisons
Gelman, A., Hill, J., & Yajima, M. (2012) · Journal of Research on Educational Effectiveness · doi:10.1080/19345747.2011.618213 · Cited by 1,274 · cited 1×
“Bayesian analyses do not require correction for multiple comparisons (16).”
BackgroundMetabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1×
“Given olanzapine’smore frequent adversemetabolic side effects (23), especially with first-episode patients (24), PORT guidelines recommend that this agent not be used for first-episode treatment.”
BackgroundCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
Self-citationTiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
Desai, H. D., Seabolt, J., & Jann, M. W. (2001) · CNS Drugs · doi:10.2165/00023210-200115060-00005 · Cited by 253
Antidepressants for people with both schizophrenia and depression
Whitehead, C., Moss, S., Cardno, A., Lewis, G., & Furtado, V. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002305 · Cited by 92
Cited by
Kane, J. M., Robinson, D. G., Schooler, N. R., Mueser, K. T., Penn, D. L., Rosenheck, R. A., Addington, J., Brunette, M. F., Correll, C. U., Estroff, S. E., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15050632 · Cited by 857
Self-citationTransforming the Treatment of Schizophrenia in the United States: The RAISE Initiative
Dixon, L. B., Goldman, H. H., Srihari, V. H., & Kane, J. M. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084934 · Cited by 112
Self-citationEmsley, R., Asmal, L., Rubio, J. M., Correll, C. U., & Kane, J. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.025 · Cited by 41
Self-citationFive year outcomes of tapering antipsychotic drug doses in a community mental health center
Steingard, S. (2018) · Community Mental Health Journal · doi:10.1007/s10597-018-0313-1 · Cited by 15
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13
“In the RAISE ‐ ETP study, ~40% of individuals had a psychopharmacology regimen that deviated from these basic recommendations, 14 and a cohort of 6246 individuals from a Medicaid claims data set found that a similar proportion of patients with early phase schizophrenia were receiving treatment that…”
Background
Metadata
- Authors
- Robinson, D. G., Schooler, N. R., John, M., Correll, C. U., Marcy, P., Addington, J., Brunette, M. F., Estroff, S. E., Mueser, K. T., Penn, D., Robinson, J., Rosenheck, R. A., Severe, J., Goldstein, A., Azrin, S., Heinssen, R., & Kane, J. M.
- Venue
- American Journal of Psychiatry
- Published
- 2015-03-01
- Volume
- 172
- Issue
- 3
- Pages
- 237-248
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2132468375
- Cited by
- 91
- References
- 8
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. https://app.cochat.ai/papers/10.1176/appi.ajp.2014.13101355
- The paper
- Robinson, D. G., Schooler, N. R., John, M., Correll, C. U., Marcy, P., Addington, J., Brunette, M. F., Estroff, S. E., Mueser, K. T., Penn, D., Robinson, J., Rosenheck, R. A., Severe, J., Goldstein, A., Azrin, S., Heinssen, R., & Kane, J. M. (2015). Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2014.13101355
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.